Compare Novavax Inc (NVAX) vs Venture Global Inc. Class A common stock (VG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Venture Global Inc. Class A common stock — how do they compare? Novavax Inc trades at $12.83 (market cap $1.82B), while Venture Global Inc. Class A common stock trades at $13.21 (market cap $33.23B). The key difference: Venture Global Inc. Class A common stock is far larger — about 18.3× Novavax Inc's market cap, and Venture Global Inc. Class A common stock pays a 1.2% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Venture Global Inc. Class A common stock for 1 Days on average.
| NVAX | VG | |
|---|---|---|
Market Cap | $1.82B | $33.23B |
Volume | 6,198,505 | 12,625,066 |
Sector | Health | Energy |
52-Week High | $12.56 | $17.53 |
52-Week Low | $6.22 | $5.92 |
Typical Hold Time | 59 Days | 1 Days |
Enterprise Value | $1.39B | $72.61B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Venture Global Inc. Class A common stock
Venture Global develops, builds, and operates liquefied natural gas export facilities. Its projects connect U.S. natural gas supply with global LNG markets.
Read more on VG →
